NEOG
NEOGEN CORP
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$11.63
−1.52%Year over year
Reported trailing growth
- Revenue
- -0.3%
- EBITDA
- +111.9%
- EBIT
- —
- EPS
- +94.7%
- Free cash flow
- +1677.8%
- Operating cash flow
- -2.0%
Forward estimates
Based on analyst estimates
- Revenue
- +0.1%
- EBITDA
- +138.4%
- EPS
- +230.3%
Three-year CAGR
- Revenue
- +1.9%
- EBITDA
- +9.9%
- EBIT
- —
- Net income
- +99.3%
- EPS
- +99.2%
- Free cash flow
- +168.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Aug 1, 2026